Td Asset Management Has Raised Mylan N V (MYL) Position By $1.75 Million; Kindred Biosciences (KIN) Has 1.39 Sentiment

Kindred Biosciences, Inc. (NASDAQ:KIN) Logo

Td Asset Management Inc increased Mylan N V (MYL) stake by 37.99% reported in 2018Q4 SEC filing. Td Asset Management Inc acquired 64,673 shares as Mylan N V (MYL)’s stock declined 17.51%. The Td Asset Management Inc holds 234,894 shares with $6.44M value, up from 170,221 last quarter. Mylan N V now has $14.49B valuation. The stock increased 0.32% or $0.09 during the last trading session, reaching $28.09. About 9.70M shares traded or 75.86% up from the average. Mylan N.V. (NASDAQ:MYL) has declined 30.99% since March 17, 2018 and is downtrending. It has underperformed by 35.36% the S&P500. Some Historical MYL News: 11/04/2018 – Mylan Reaffirms 2018 Guidance; 29/03/2018 – Flutiform ( fluticasone propionate + formoterol fumarate ; Vectura/Mundipharma/Kyorin) Drug Analysis 2018 –; 13/04/2018 – Drug maker Mylan is in advanced discussions to acquire Merck’s consumer health business, people familiar with the matter said; 10/05/2018 – Mylan: Civil Investigative Demand Concerns Trade Agreements Act Compliance; 28/03/2018 – Moody’s Assigns Baa3 To Mylan’s Offering; 13/04/2018 – MYLAN IN DISCUSSIONS TO ACQUIRE MERCK KGAA’S CONSUMER HEALTH UNIT; 09/05/2018 – MYLAN 1Q ADJ EPS 96C, EST. 96C; 20/04/2018 – FDA: Abbreviated New Drug Application (ANDA): 210364 Company: MYLAN PHARMS INC; 09/05/2018 – Mylan’s EpiPen Added to FDA List of Medications in Short Supply; 24/04/2018 – AT LEAST TWO COMPANIES ARE ON TRACK TO BE INDICTED IN THE COMING MONTHS, IN ADDITION TO SEVERAL EXECUTIVES – BLOOMBERG, CITING

Kindred Biosciences Inc (KIN) investors sentiment decreased to 1.39 in Q4 2018. It’s down -0.85, from 2.24 in 2018Q3. The ratio dropped, as 39 hedge funds opened new and increased stock positions, while 28 sold and trimmed stock positions in Kindred Biosciences Inc. The hedge funds in our database now own: 21.29 million shares, down from 21.65 million shares in 2018Q3. Also, the number of hedge funds holding Kindred Biosciences Inc in top ten stock positions was flat from 1 to 1 for the same number . Sold All: 11 Reduced: 17 Increased: 28 New Position: 11.

Park West Asset Management Llc holds 3.25% of its portfolio in Kindred Biosciences, Inc. for 6.00 million shares. Granahan Investment Management Inc Ma owns 784,862 shares or 0.61% of their US portfolio. Moreover, Silverback Asset Management Llc has 0.57% invested in the company for 283,191 shares. The New York-based General American Investors Co Inc has invested 0.52% in the stock. Eam Investors Llc, a California-based fund reported 149,257 shares.

Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company has market cap of $356.30 million. The companyÂ’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. It currently has negative earnings. The Company’s lead product candidates include Zimeta, a dipyrone injection for the control of pyrexia in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

Since January 1, 0001, it had 1 insider purchase, and 5 insider sales for $4.94 million activity.

More notable recent Kindred Biosciences, Inc. (NASDAQ:KIN) news were published by: which released: “Kindred Bio: Call Me Inappetent – Seeking Alpha” on March 12, 2019, also with their article: “Coupa (COUP) Q4 Earnings and Revenues Surpass Estimates – Nasdaq” published on March 12, 2019, published: “Seelos Therapeutics and Bio-Path Holdings among healthcare gainers; Aptevo Therapeutics leads the losers – Seeking Alpha” on March 07, 2019. More interesting news about Kindred Biosciences, Inc. (NASDAQ:KIN) were released by: and their article: “64 Biggest Movers From Yesterday – Benzinga” published on March 08, 2019 as well as‘s news article titled: “51 Stocks Moving In Thursday’s Mid-Day Session – Benzinga” with publication date: March 07, 2019.

The stock increased 0.66% or $0.06 during the last trading session, reaching $9.17. About 218,520 shares traded. Kindred Biosciences, Inc. (KIN) has risen 22.47% since March 17, 2018 and is uptrending. It has outperformed by 18.10% the S&P500. Some Historical KIN News: 24/04/2018 – KIN: FDA SAYS APPROVAL IS PENDING PRE-APPROVAL INSPECTION; 07/05/2018 – Kindred Biosciences Receives FDA Approval Of Mirataz(TM) (mirtazapine Transdermal Ointment) For The Management Of Weight Loss In Cats; 30/05/2018 – KindredBio Announces Positive Results from Pilot Effectiveness Study of KIND-014 for the Treatment of Gastric Ulcers in Horses; 07/05/2018 – KINDRED BIOSCIENCES GETS FDA APPROVAL OF MIRATAZ™ (MIRTAZAPINE; 24/05/2018 – Kindred Biosciences Presenting at Conference May 30; 24/04/2018 – Kindred Biosciences Received Response From FDA for Chemistry, Manufacturing, and Controls Technical Section for Zimeta IV; 07/05/2018 – KINDRED BIOSCIENCES SAYS ENTERED INTO AT MARKET ISSUANCE SALES AGREEMENT – SEC FILING; 07/05/2018 – Kindred Biosciences Receives FDA Approval of Mirataz™ (mirtazapine transdermal ointment) for the Management of Weight Loss in; 07/05/2018 – FDA approves Kindred’s weight-loss ointment for cats; 24/04/2018 – KINDRED BIOSCIENCESINC – FDA HAS NO ADDITIONAL QUESTIONS OR REQUESTS REGARDING SUBMISSION OF TECHNICAL SECTION FOR ZIMETA IV

Td Asset Management Inc decreased Magnolia Oil & Gas Corp stake by 753,100 shares to 724,713 valued at $8.12M in 2018Q4. It also reduced Buckle Inc (NYSE:BKE) stake by 92,000 shares and now owns 59,200 shares. Colgate Palmolive Co (NYSE:CL) was reduced too.

Investors sentiment decreased to 0.33 in 2018 Q4. Its down 1.17, from 1.5 in 2018Q3. It worsened, as 1 investors sold MYL shares while 2 reduced holdings. 1 funds opened positions while 0 raised stakes. 129,903 shares or 38.96% less from 212,833 shares in 2018Q3 were reported. Gemmer Asset Mgmt Limited Liability Corporation has invested 0% of its portfolio in Mylan N.V. (NASDAQ:MYL). Gulf Int Natl Bank (Uk) has 115,438 shares.

More notable recent Mylan N.V. (NASDAQ:MYL) news were published by: which released: “Notable Thursday Option Activity: MYL, JNJ, BMY – Nasdaq” on March 14, 2019, also with their article: “Mylan (MYL): Big Drop Sets Up A Contrarian Value Play – Nasdaq” published on February 28, 2019, published: “Mylan (MYL) to Report Q4 Earnings: What’s in the Offing? – Nasdaq” on February 20, 2019. More interesting news about Mylan N.V. (NASDAQ:MYL) were released by: and their article: “Mylan (MYL) Q4 Earnings & Revenues Miss Estimates, Stock Down – Nasdaq” published on February 27, 2019 as well as‘s news article titled: “Why Mylan Shares Will Rebound This Year – Seeking Alpha” with publication date: March 05, 2019.

Among 15 analysts covering Mylan (NASDAQ:MYL), 11 have Buy rating, 0 Sell and 4 Hold. Therefore 73% are positive. Mylan had 20 analyst reports since October 5, 2018 according to SRatingsIntel. Morgan Stanley downgraded Mylan N.V. (NASDAQ:MYL) rating on Tuesday, October 9. Morgan Stanley has “Equal-Weight” rating and $36 target. Citigroup maintained Mylan N.V. (NASDAQ:MYL) on Tuesday, November 6 with “Buy” rating. The stock has “Buy” rating by J.P. Morgan on Wednesday, February 27. Raymond James maintained the shares of MYL in report on Wednesday, February 27 with “Buy” rating. The stock has “Buy” rating by Bank of America on Tuesday, November 6. The stock of Mylan N.V. (NASDAQ:MYL) earned “Overweight” rating by Morgan Stanley on Wednesday, March 6. The stock has “Buy” rating by RBC Capital Markets on Wednesday, February 27. On Wednesday, February 27 the stock rating was maintained by Cowen & Co with “Hold”. The company was maintained on Tuesday, February 26 by Cantor Fitzgerald. The stock of Mylan N.V. (NASDAQ:MYL) earned “Neutral” rating by Mizuho on Friday, October 5.

Kindred Biosciences, Inc. (NASDAQ:KIN) Institutional Positions Chart